Organization (Industry)
IPCA LABORATORIES LIMITED
ClinicalTrials.gov lists IPCA LABORATORIES LIMITED as lead sponsor of 30 trials, counting the companies grouped under it. IPCA LABORATORIES LIMITED itself has 11 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers IPCA LABORATORIES LIMITED and 1 company grouped under it: 30 lead-sponsored trials (30 its own, 0 in the grouped companies) and 4 legal-entity registrations (2 its own, 2 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| UNICHEM LABORATORIES LIMITED | 0 | 2 |
Disease areas (3)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dyslipidemias | 12 |
| Hypoalphalipoproteinemias | 12 |
| Lecithin Cholesterol Acyltransferase Deficiency | 12 |
Trials by start year as sponsor or collaborator (5)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2013 | 3 |
| 2012 | 21 |
| 2011 | 5 |
| 2007 | 1 |
| 2006 | 1 |
Recruitment duration, a model prediction: none of the 30 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (11)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Quetiapine | 2 |
| Ondansetron | 2 |
| Etodolac | 2 |
| Lisinopril | 2 |
| Risperidone | 2 |
Showing 5 of 11 approved assets.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 39 | 6 | 2025-05-06 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 18 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 127 | 2026-08-13 |
Manufacturing and distribution sites (10)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Ipca Laboratories Limited | Ratlam, IN | EMA, FDA, Health Canada | |
| Ipca Laboratories Limited | Palghar, IN | FDA | |
| Ipca Laboratories Limited | Dhar, IN | EMA, FDA, Health Canada | |
| Ipca Laboratories Limited | Silvassa, IN | FDA, Health Canada | |
| IPCA Laboratories Limited | Gandhidham, IN | EMA |
Showing 5 of 10 sites.
Latest dated events (277)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-07 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-07 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 277 events.
Biomarker capability evidence (20)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| PAPOLA | Trial sponsor | Named in trial exclusion criteria |
| PAPOLA | Trial sponsor | Named in trial exclusion criteria |
| PAPOLA | Trial sponsor | Named in trial exclusion criteria |
| PAPOLA | Trial sponsor | Named in trial exclusion criteria |
| PAPOLA | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 20 evidence rows.
Biomarkers this organization publishes on (1)
| Biomarker | Publications |
|---|---|
| FGB | 1 |
On Scientist.com
IPCA LABORATORIES LIMITED is listed as a research supplier in the Scientist.com network.
Service areas
Ipca is a pharmaceutical company which provides formulations and APIs to various therapeutics segments.
- Website
- www.ipcalabs.com
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sponsor delivery record, journals published in, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Work with Ipca on Scientist.com
For prices, more details, or to contact Ipca, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.